Get to know our clinical trials
Clinical trial to evaluate the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C combined with surgery versus surgery alone in locally advanced colorectal carcinoma (FOXHIPECT4).
THE PRIMARY OBJECTIVE IS TO DETERMINE WHETHER PROACTIVE NEOADJUVANT SYSTEMIC TREATMENT (FOLFOX), WITH OR WITHOUT HIPEC WITH MITOMYCIN C, FOLLOWED BY POSTOPERATIVE ADJUVANT SYSTEMIC TREATMENT, INCREASES 36-MONTH DISEASE-FREE SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED COLON CANCER COMPARED WITH STANDARD TREATMENT.
Technical Summary
- MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE ADJUVANT EFFECT OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) WITH MITOMYCIN C COMBINED WITH SURGERY VERSUS SURGERY ALONE IN LOCALLY ADVANCED COLORECTAL CARCINOMA (FOXHIPECT4).
- Code EudraCT: 2025-520471-29-00
- Protocol number: FCO-FOX-2024-01
- Promoter: FIBICO
- Molecule/Drug: Mitomicina C
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.